Why in news?
The Swiss medicines regulator approved Coartem Baby, the first antimalarial drug specifically formulated for infants weighing 2–5 kilograms. The approval marks a milestone in paediatric malaria treatment.
What is Coartem Baby?
- Coartem Baby is a dispersible formulation of artemether–lumefantrine, the gold‑standard combination therapy for Plasmodium falciparum malaria.
- Developed by Novartis in collaboration with the Medicines for Malaria Venture, it is designed for babies too young for existing tablet or powder formulations.
Key features
- Infant‑friendly: The drug dissolves easily in water or milk and has a cherry flavour to improve adherence.
- Tailored dosage: Each sachet contains the right amount of drug for small infants, removing the need for splitting adult doses.
- Safety and efficacy: Clinical trials have shown high cure rates with minimal side effects. Two doses per day over three days complete the course.
Impact
- Fills a critical treatment gap for newborns and infants who are highly vulnerable to malaria but cannot use existing drugs.
- Expected to be approved by regulators in several African countries and the World Health Organization, potentially saving thousands of lives.
- Eliminates off‑label dosing, improving accuracy and reducing drug resistance.
